MYC levels govern hematopoietic tumor type and latency in transgenic mice

Blood

Volumn 108, Issue 2, 2006, Pages 653-661

  Smith, Darrin P ^a   Bath, Mary L ^a   Metcalf, Donald ^a   Harris, Alan W ^a   Cory, Suzanne ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; MYC PROTEIN; PROTEIN BCL 2; VAV PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREEDING METHOD; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE EXPRESSION; GENE VECTOR; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; KINETICS; LATENT PERIOD; MEGAKARYOCYTE; MOUSE; NONHUMAN; ONCOGENE MYC; PHENOTYPIC VARIATION; PRIORITY JOURNAL; T CELL LYMPHOMA; THYMOCYTE; TRANSGENIC ANIMAL;

EID: 33646339095     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-01-0172     Document Type: Article

References (51)

1. Fernandez PC, Frank SR, Wang L, et al. Genomic targets of the human c-Myc protein. Genes Dev. 2003;17:1115-1129.
2. Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci U S A. 2003;100:8164-8169.
3. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Ann Rev Cell Dev Biol. 2000;16:653-699.
4. Henriksson M, Luscher B. Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv Cancer Res. 1996;68:109-182.
5. Soucek L, Evan G. Myc-Is this the oncogene from Hell? Cancer Cell. 2002;1:406-408.
6. Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. Oncogene. 2003;22:9007-9021.
7. Cory S. Activation of cellular oncogenes in hemopoietic cells by chromosome translocation. Adv in Cancer Res. 1986;47:189-234.
8. Marcu KB, Bossone SA, Patel AJ. myc function and regulation. Annu Rev Biochem. 1992;61:809-860.
9. Sanchez-Beato M, Sanchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood. 2003;101:1220-1235.
10. Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene. 2001;20:5595-5610.
11. Amati B. Myc degradation: dancing with ubiquitin ligases. Proc Natl Acad Sci U S A. 2004;101:8843-8844.
12. Dominguez-Sola D, Dalla-Favera R. PINning down the c-Myc oncoprotein. Nat Cell Biol. 2004;6:288-289.
13. Sears RC. The life cycle of c-Myc: from synthesis to degradation. Cell Cycle. 2004;3:1133-1137.
14. Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985;318:533-538.
15. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. The Eμ-myc transgenic mouse: a model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med. 1988;167:353-371.
16. Langdon WY, Harris AW, Cory S, Adams JM. The c-myc oncogene perturbs B lymphocyte development in Eμ-myc transgenic mice. Cell. 1986;47:11-18.
17. Adams JM, Harris AW, Strasser A, Ogilvy S, Cory S. Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector. Oncogene. 1999;18:5268-5277.
18. Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature. 1990;348:331-333.
19. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999;13:2658-2669.
20. Egle A, Harris AW, Bouillet P, Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci U S A. 2004;101:6164-6169.
21. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 1999;4:199-207.
22. Bachireddy P, Bendapudi PK, Felsher DW. Getting at MYC through RAS. Clin Cancer Res. 2005;11:4278-4781.
23. Ogilvy S, Metcalf D, Gibson L, Bath ML, Harris AW, Adams JM. Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment. Blood. 1999;94:1855-1863.
24. Ogilvy S, Metcalf D, Print CG, Bath ML, Harris AW, Adams JM. Constitutive bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc Natl Acad Sci U S A. 1999;96:14943-14948.
25. Smith DP, Bath ML, Harris AW, Cory S. T-cell lymphomas mask slower developing B-lymphoid and myeloid tumors in transgenic mice with broad hematopoietic expression of MYC. Oncogene. 2005;24:3544-3553.
26. Bath ML. Simple and efficient in vitro fertilization with cryopreserved C57BL/6J mouse sperm. Biol Reprod. 2003;68:19-23.
27. Egle A, Harris AW, Bath ML, O'Reilly L, Cory S. VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood. 2004;103:2276-2283.
28. Metcalf D, Di Rago L, Mifsud S. Synergistic and inhibitory interactions in the in vitro control of murine megakaryocyte colony formation. Stem Cells. 2002;20:552-560.
29. Alexander WS, Schrader JW, Adams JM. Expression of the c-myc oncogene under control of an immunoglobulin enhancer in Eμ-myc transgenic mice. Mol Cell Biol. 1987;7:1436-1444.
30. Kogan SC, Ward JM, Anver MR, et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood. 2002;100:238-245.
31. Shivdasani RA. Molecular and transcriptional regulation of megakaryocyte differentiation. Stem Cells. 2001;19:397-407.
32. Gandarillas A, Davies D, Blanchard JM. Normal and c-Myc-promoted human keratinocyte differentiation both occur via a novel cell cycle involving cellular growth and endoreplication. Oncogene. 2000;19:3278-3789.
33. Edgar BA, Orr-Weaver TL. Endoreplication cell cycles: more for less. Cell. 2001;105:297-306.
34. Bobik R, Dabrowski Z. Emperipolesis of marrow cells within megakaryocytes in the bone marrow of sublethally irradiated mice. Ann Hematol. 1995;70:91-95.
35. McGarry MP, Reddington M, Jackson CW, Zhen L, Novak EK, Swank RT. Increased incidence and analysis of emperipolesis in megakaryocytes of the mouse mutant gunmetal. Exp Mol Pathol. 1999;66:191-200.
36. Schmitt A, Jouault H, Guichard J, Wendling F, Drouin A, Cramer EM. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. Blood. 2000;96:1342-1347.
37. White JG. Structural defects in inherited and giant platelet disorders. Adv Hum Genet. 1990;19:133-234.
38. Pileri SA, Grogan TM, Harris NL, et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology. 2002;41:1-29.
39. Stewart M, Cameron E, Campbell M, et al. Conditional expression and oncogenicity of c-myc linked to a CD2 gene dominant control region. Int J Cancer. 1993;53:1023-1030.
40. Cory S, Huang DCS, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene. 2003;22:8590-8607.
41. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell. 2002;2:103-112.
42. Oda E, Ohki R, Murasawa H, et al. Noxa, a BH3-only member of the bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000;288:1053-1058.
43. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell. 2001;7:683-694.
44. L or Bcl-2 is bypassed during lymphomagenesis. Mol Cell Biol. 2001;21:5063-5070.
45. L and c-myc. J Immunol. 2004;172:6684-6691.
46. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 1999;13:2670-2677.
47. Hemann MT, Zilfou JT, Zhao Z, Burgess DJ, Hannon GJ, Lowe SW. Suppression of tumorigenesis by the p53 target PUMA. Proc Natl Acad Sci U S A. 2004;101:9333-9338.
48. Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood. 2004;104:3009-3020.
49. Hemann MT, Bric A, Teruya-Feldstein J, et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature. 2005;436:807-811.
50. Tagawa H, Karnan S, Suzuki R, et al. Genomewide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene. 2005;24:1348-1358.
51. Nilsson JA, Cleveland JL. MNT: master regulator of the Max network. Cell Cycle. 2004;3:588-590.